Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal DysfunctionA Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Ronald M. Witteles, MD*,*,
David Kao, MD*,
Dianne Christopherson, PhD, RN*,
Kelly Matsuda, PharmD*,
Randall H. Vagelos, MD, FACC*,
Donald Schreiber, MD , and
Michael B. Fowler, MB, FACC*
* Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California
Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California
Palo Alto Veterans Administration Hospital, Palo Alto, California.
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Incidence of Worsened Renal Function
Incidence of  20% rise in creatinine (Cr) by discharge or day 7 of the hospitalization. No significant difference was observed in the primary end point of worsened renal function (increase in serum creatinine 20%) (p = 0.85).
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Blood Pressure Change During Infusion
Blood pressure change is recorded in reference to the start of the infusion (time = 0). Time "off" refers to 3 h after the infusion was stopped (solid lines = systolic blood pressure change; dashed lines = diastolic blood pressure change; green = placebo; red = nesiritide). p < 0.05 versus placebo at 6 and 12 h for systolic blood pressure, and at 3 h for diastolic blood pressure.
|
|
|
